Company Details
macleods-pharmaceuticals-ltd.
11,821
143,576
3254
macleodspharma.com
0
MAC_2163538
In-progress


MACLEODS PHARMACEUTICALS LTD. Company CyberSecurity Posture
macleodspharma.comA vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
Company Details
macleods-pharmaceuticals-ltd.
11,821
143,576
3254
macleodspharma.com
0
MAC_2163538
In-progress
Between 750 and 799

MPL Global Score (TPRM)XXXX



No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2026.
No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2026.
No incidents recorded for MACLEODS PHARMACEUTICALS LTD. in 2026.
MPL cyber incidents detection timeline including parent company and subsidiaries

A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.


Glenmark Pharmaceuticals Limited is a research-led, global organization committed to enriching lives. Innovation is deeply embedded in Glenmark’s culture; it is how we differentiate ourselves in our key markets and create greater value for our stakeholders. In our journey of innovation over the pa

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics

We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and
At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out mor
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating wit

Intas is one of the leading multinational pharmaceutical formulation development, manufacturing, and marketing organization in the world. It has been growing at 19% CAGR and crossed the $2.5 billion mark in the past financial year. The company has set up a network of subsidiaries, under the name Acc
At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently addre
Torrent Pharma, with annual revenues of more than Rs 10,700 crores, is the flagship Company of the Torrent Group, with group revenues of Rs 41,000 crores. It is ranked 5th in the Indian Pharma Market and is among the Top 5 in the therapeutic segments of Cardiovascular (CV), Central Nervous System (C
.png)
The event garnered deep insights into current trends, challenges, and opportunities, engaging over 175 senior delegates, industry leaders, and innovators.

Explore insights on cybersecurity incidents, risk posture, and Rankiteo's assessments.
The official website of MACLEODS PHARMACEUTICALS LTD. is https://www.macleodspharma.com.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD.’s AI-generated cybersecurity score is 775, reflecting their Fair security posture.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. is not certified under SOC 2 Type 1.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. does not hold a SOC 2 Type 2 certification.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. is not listed as GDPR compliant.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. does not currently maintain PCI DSS compliance.
According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. is not compliant with HIPAA regulations.
According to Rankiteo,MACLEODS PHARMACEUTICALS LTD. is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.
MACLEODS PHARMACEUTICALS LTD. operates primarily in the Pharmaceutical Manufacturing industry.
MACLEODS PHARMACEUTICALS LTD. employs approximately 11,821 people worldwide.
MACLEODS PHARMACEUTICALS LTD. presently has no subsidiaries across any sectors.
MACLEODS PHARMACEUTICALS LTD.’s official LinkedIn profile has approximately 143,576 followers.
MACLEODS PHARMACEUTICALS LTD. is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.
No, MACLEODS PHARMACEUTICALS LTD. does not have a profile on Crunchbase.
Yes, MACLEODS PHARMACEUTICALS LTD. maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/macleods-pharmaceuticals-ltd..
As of January 24, 2026, Rankiteo reports that MACLEODS PHARMACEUTICALS LTD. has not experienced any cybersecurity incidents.
MACLEODS PHARMACEUTICALS LTD. has an estimated 5,511 peer or competitor companies worldwide.
Total Incidents: According to Rankiteo, MACLEODS PHARMACEUTICALS LTD. has faced 0 incidents in the past.
Incident Types: The types of cybersecurity incidents that have occurred include .
.png)
Improper validation of specified type of input in M365 Copilot allows an unauthorized attacker to disclose information over a network.
Improper access control in Azure Front Door (AFD) allows an unauthorized attacker to elevate privileges over a network.
Azure Entra ID Elevation of Privilege Vulnerability
Moonraker is a Python web server providing API access to Klipper 3D printing firmware. In versions 0.9.3 and below, instances configured with the "ldap" component enabled are vulnerable to LDAP search filter injection techniques via the login endpoint. The 401 error response message can be used to determine whether or not a search was successful, allowing for brute force methods to discover LDAP entries on the server such as user IDs and user attributes. This issue has been fixed in version 0.10.0.
Runtipi is a Docker-based, personal homeserver orchestrator that facilitates multiple services on a single server. Versions 3.7.0 and above allow an authenticated user to execute arbitrary system commands on the host server by injecting shell metacharacters into backup filenames. The BackupManager fails to sanitize the filenames of uploaded backups. The system persists user-uploaded files directly to the host filesystem using the raw originalname provided in the request. This allows an attacker to stage a file containing shell metacharacters (e.g., $(id).tar.gz) at a predictable path, which is later referenced during the restore process. The successful storage of the file is what allows the subsequent restore command to reference and execute it. This issue has been fixed in version 4.7.0.

Get company history
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Identify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.
Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.
Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.
Leverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.